184 related articles for article (PubMed ID: 33557379)
1. Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting.
Miranda A; Santos T; Largy E; Cruz C
Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33557379
[TBL] [Abstract][Full Text] [Related]
2. G-Quadruplex Aptamer-Ligand Characterization.
Moreira D; Leitão D; Lopes-Nunes J; Santos T; Figueiredo J; Miranda A; Alexandre D; Tomaz C; Mergny JL; Cruz C
Molecules; 2022 Oct; 27(20):. PubMed ID: 36296374
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of a DNA aptamer by ligand binding.
Santos T; Lopes-Nunes J; Alexandre D; Miranda A; Figueiredo J; Silva MS; Mergny JL; Cruz C
Biochimie; 2022 Sep; 200():8-18. PubMed ID: 35550917
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-based approaches to detect nucleolin in prostate cancer.
Miranda A; Santos T; Carvalho J; Alexandre D; Jardim A; Caneira CF; Vaz V; Pereira B; Godinho R; Brito D; Chu V; Conde JP; Cruz C
Talanta; 2021 May; 226():122037. PubMed ID: 33676639
[TBL] [Abstract][Full Text] [Related]
5. RNA G-quadruplex as supramolecular carrier for cancer-selective delivery.
Santos T; Pereira P; Campello MPC; Paulo A; Queiroz JA; Cabrita E; Cruz C
Eur J Pharm Biopharm; 2019 Sep; 142():473-479. PubMed ID: 31325486
[TBL] [Abstract][Full Text] [Related]
6. Targeting nucleolin by RNA G-quadruplex-forming motif.
Figueiredo J; Miranda A; Lopes-Nunes J; Carvalho J; Alexandre D; Valente S; Mergny JL; Cruz C
Biochem Pharmacol; 2021 Jul; 189():114418. PubMed ID: 33460627
[TBL] [Abstract][Full Text] [Related]
7. Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers.
Riccardi C; Musumeci D; Russo Krauss I; Piccolo M; Irace C; Paduano L; Montesarchio D
Int J Biol Macromol; 2018 Oct; 118(Pt B):1384-1399. PubMed ID: 30170359
[TBL] [Abstract][Full Text] [Related]
8. AS1411-functionalized delivery nanosystems for targeted cancer therapy.
Kozani PS; Kozani PS; Malik MT
Explor Med; 2021; 2():146-166. PubMed ID: 34723284
[TBL] [Abstract][Full Text] [Related]
9. AS1411 derivatives as carriers of G-quadruplex ligands for cervical cancer cells.
Figueiredo J; Lopes-Nunes J; Carvalho J; Antunes F; Ribeiro M; Campello MPC; Paulo A; Paiva A; Salgado GF; Queiroz JA; Mergny JL; Cruz C
Int J Pharm; 2019 Sep; 568():118511. PubMed ID: 31301466
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
[TBL] [Abstract][Full Text] [Related]
11. The G-quadruplex-forming aptamer AS1411 potently inhibits HIV-1 attachment to the host cell.
Perrone R; Butovskaya E; Lago S; Garzino-Demo A; Pannecouque C; Palù G; Richter SN
Int J Antimicrob Agents; 2016 Apr; 47(4):311-6. PubMed ID: 27032748
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Aptamer as a Potential Drug Targeted Delivery for Retinal Angiogenesis Inhibition.
Moreira D; Lopes-Nunes J; Santos FM; Campello MPC; Oliveira MC; Paulo A; Tomaz C; Cruz C
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242534
[TBL] [Abstract][Full Text] [Related]
13. Biological studies of an ICG-tagged aptamer as drug delivery system for malignant melanoma.
Lopes-Nunes J; Lifante J; Shen Y; Ximendes EC; Jaque D; Iglesias-de la Cruz MC; Cruz C
Eur J Pharm Biopharm; 2020 Sep; 154():228-235. PubMed ID: 32707287
[TBL] [Abstract][Full Text] [Related]
14. G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms.
Bates PJ; Reyes-Reyes EM; Malik MT; Murphy EM; O'Toole MG; Trent JO
Biochim Biophys Acta Gen Subj; 2017 May; 1861(5 Pt B):1414-1428. PubMed ID: 28007579
[TBL] [Abstract][Full Text] [Related]
15. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
[TBL] [Abstract][Full Text] [Related]
16. A Non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.
Liu Y; Hu B; Pei X; Li J; Qi D; Xu Y; Ou H; Wu Y; Xue L; Huang JH; Wu E; Hu X
Adv Healthc Mater; 2023 Aug; 12(20):e2300791. PubMed ID: 37262080
[TBL] [Abstract][Full Text] [Related]
17. Nucleolin Discriminates Drastically between Long-Loop and Short-Loop Quadruplexes.
Saha A; Duchambon P; Masson V; Loew D; Bombard S; Teulade-Fichou MP
Biochemistry; 2020 Mar; 59(12):1261-1272. PubMed ID: 32191439
[TBL] [Abstract][Full Text] [Related]
18. Aptamer-based tumor-targeted drug delivery for photodynamic therapy.
Shieh YA; Yang SJ; Wei MF; Shieh MJ
ACS Nano; 2010 Mar; 4(3):1433-42. PubMed ID: 20166743
[TBL] [Abstract][Full Text] [Related]
19. Aptamer AS1411 utilized for super-resolution imaging of nucleolin.
Jing Y; Cai M; Zhou L; Jiang J; Gao J; Wang H
Talanta; 2020 Sep; 217():121037. PubMed ID: 32498876
[TBL] [Abstract][Full Text] [Related]
20. Systematic Evaluation of Benchmark G4 Probes and G4 Clinical Drugs using three Biophysical Methods: A Guideline to Evaluate Rapidly G4-Binding Affinity.
Laigre E; Bonnet H; Beauvineau C; Lavergne T; Verga D; Defrancq E; Dejeu J; Teulade-Fichou MP
Chembiochem; 2024 Apr; ():e202400210. PubMed ID: 38619969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
